Global Pharma IP Forum: Novartis questions UPC agreement

A counsel for pharmaceutical company Novartis has said he “embraces” the Unified Patent Court (UPC), but has concerns about securing preliminary injunctions and the harmonisation of supplementary protection certificates (SPC) under the agreement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gene tech firm fends off injunction in test kit dispute

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

Global Pharma IP Forum: Novartis questions UPC agreement

Editor's picks

Editor's picks

More features